Platelet aggregation inhibitory activity of selective A2 adenosine receptor agonists.

A series of new 2-alkynyl, 2-cycloalkynyl, and 2-aralkynyl derivs. of adenosine-5'-ethyluronamide (NECA) were evaluated in binding studies and functional assays to assess their potency and selectivity at A2 vs. A1 receptors. The new derivs. were also tested as inhibitors of rabbit platelet aggregation induced by ADP. While the presence of an arom. or heteroarom. ring conjugated to the triple bond decreased antiplatelet activity, the introduction of a hydroxyl group or a heterocyclic ring on the alkynyl side chain increased the antiaggregatory activity in comparison with NECA, resulting in the most potent inhibitors of platelet aggregation so far known in the nucleoside series. However, the presence of an α-quaternary carbon markedly reduced the antiaggregatory potency without affecting the A2 binding affinity, suggesting that the platelet receptor is not a typical A2a site.